Targeting drug-resistant breast cancers using enzyme-stimulating peptides
Official title: New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
Funded at University of North Texas · NIH-10909182 · Data updated 2026-11-12
This study is exploring a new treatment for triple-negative breast cancer that uses specially designed molecules to help stop the cancer cells from growing, and if successful, it could offer hope for patients who currently have limited options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas NIH-funded |
| Lab location | 1 site (Denton, United States) |
| Project start | August 17, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $180,300 |
| NIH project number | 5R16GM150848-02 |
| Project ID | NIH-10909182 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with triple-negative breast cancer who have not responded to conventional treatments.
✕Less likely to help
Patients with other types of breast cancer that respond to hormonal therapies may not benefit from this research.
What this research studies
This research focuses on developing new treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that does not respond to standard hormonal therapies. The approach involves using specially designed peptides that interact with the Eyes Absent enzyme (EYA) to inhibit the growth of TNBC cells. By leveraging the unique enzymatic properties of EYA, the researchers aim to create nanostructures that can induce cell death specifically in TNBC cells, offering a novel therapeutic strategy. Patients may benefit from this innovative treatment if it proves effective in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with drug-resistant breast cancers.
How similar studies have gone: While the approach of using enzymatic reactions to target cancer cells is innovative, similar strategies have shown promise in other cancer types, suggesting potential for success in this area.
Where this research is happening
-
University of North Texas
Denton, United States Active
Researchers
- Principal investigator: Habibi, Neda — University of North Texas
- Study coordinator: Habibi, Neda
Related research
Other NIH-funded projects on the same topics.
-
Cataracts and Work Exposures in Denmark
A large Danish study will look at whether job-related exposures, both chemical and non-chemical, are linked to developing cataracts.
-
New approach to find noninvasive brain networks that predict epilepsy after brain injury
A study aims to identify noninvasive brain biomarkers that can forecast epileptogenesis after brain injury by linking MRI network patterns with EEG signals.
-
Off-the-shelf ADC-NK cell therapy platform for cancer and immune diseases
A universal, ready-to-use natural killer cell therapy armed with antibody-drug conjugates is being developed to target cancers and other diseases.
-
New and better ways to measure kids' exposure to air pollution and traffic
This project looks at how traffic-related air pollution and green space around homes may affect cancer risk in children and uses advanced exposure measurements to better understand these links.
-
Can a single model work for high-resolution 3D genome structure using generalizable methods
A grantfunds researchers to create high-resolution 3D genome models that can work across different cell types using advanced algorithms and machine learning.
-
How tissue stiffness and stretching affect nanoparticle delivery in cancer and other diseases
This grant studies how the physical properties of tissues, like stiffness and stretch, influence how nanoparticles are taken up by cancer-related cells to improve future therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.